UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 options and sold 9,500 United Therapeutics (UTHR) common shares held by a trust in multiple trades around $529–$535 under a 10b5-1 plan.

On July 24, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equivalent number of common shares, then immediately sold those 9,500 shares in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The sales were executed in multiple tranches between approximately $528.72 and $535.03 per share, totaling 9,500 shares sold and generating proceeds of roughly $5.05 million. Following these transactions, trust and related family holdings still retain several hundred thousand shares of United Therapeutics common stock across various direct and indirect forms of ownership, and the option exercise reduced the corresponding stock option position while increasing and then monetizing common stock held by the trust.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000106

Alert Tier

7